Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrara

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 18, 2026
Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysisPietro Bertoglio, Filippo Tommaso Gallina, Eleonora Balzani, et al.
Lung Cancer (Amsterdam, Netherlands)|October 4, 2025
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trialsFrancesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, et al.
Critical Reviews in Oncology/Hematology|December 18, 2025
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysisFabio Salomone, Massimo Di Maio, Angela Viggiano, et al.
Journal of Personalized Medicine|June 2, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase InhibitorsMario Occhipinti, Marta Brambilla, Giulia Galli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Critical Reviews in Oncology/Hematology|September 24, 2024
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481]Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology|August 19, 2024
Unleashing precision: A review of targeted approaches in pleural mesotheliomaMario Occhipinti, Marta Brambilla, Raimondo Di Liello, et al.
Translational Lung Cancer Research|November 19, 2020
<i>SMO</i> mutations confer poor prognosis in malignant pleural mesotheliomaDiego Signorelli, Claudia Proto, Laura Botta, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 18, 2026
Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysisPietro Bertoglio, Filippo Tommaso Gallina, Eleonora Balzani, et al.
Lung Cancer (Amsterdam, Netherlands)|October 4, 2025
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trialsFrancesco Guerrera, Filippo Tommaso Gallina, Eleonora Balzani, et al.
Critical Reviews in Oncology/Hematology|December 18, 2025
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysisFabio Salomone, Massimo Di Maio, Angela Viggiano, et al.
Journal of Personalized Medicine|June 2, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase InhibitorsMario Occhipinti, Marta Brambilla, Giulia Galli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLCRoss A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.
Cancers|October 3, 2020
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)Andrea De Giglio, Laura Mezquita, Edouard Auclin, et al.
Critical Reviews in Oncology/Hematology|September 24, 2024
Erratum to "Unleashing precision: A review of targeted approaches in pleural mesothelioma" [Crit. Rev. Oncol./Hematol. 203C (2024) 104481]Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology|August 19, 2024
Unleashing precision: A review of targeted approaches in pleural mesotheliomaMario Occhipinti, Marta Brambilla, Raimondo Di Liello, et al.
Translational Lung Cancer Research|November 19, 2020
<i>SMO</i> mutations confer poor prognosis in malignant pleural mesotheliomaDiego Signorelli, Claudia Proto, Laura Botta, et al.
Pageof 15